Diagnostic performances of PCR-based T-cell clonality assessment and mutation detection through targeted NGS (t-NGS) in T-cell lymphoma diagnosis
| . | . | . | Diagnosis . | Diagnostic performances . | |||
|---|---|---|---|---|---|---|---|
| . | . | . | TCL . | BTC . | Se (%) . | Sp (%) . | Accuracy (%) . |
| (95% CI) . | (95% CI) . | (95% CI) . | |||||
| Test cohort (N = 57) | PCR | + | 39 | 7 | 95.1 (83.5-99.4) | 41.7 (15.2-72.3) | 83.0 (70.2-91.9) |
| − | 2 | 5 | |||||
| NC | 3 | 1 | |||||
| t-NGS | + | 42 | 0 | 95.5 (84.5-99.4) | 100.0 (75.3-100.0)* | 96.5 (87.9-99.6) | |
| − | 2 | 13 | |||||
| NC | 0 | 0 | |||||
| Validation cohort (N = 50) | PCR | + | 35 | 6 | 94.6 (81.8-99.3) | 45.5 (16.7-76.6) | 83.3 (69.8-92.5) |
| − | 2 | 5 | |||||
| NC | 1 | 1 | |||||
| t-NGS | + | 37 | 0 | 97.4 (86.2-99.9) | 100.0 (73.5-100.0)* | 98.0 (89.4-99.9) | |
| − | 1 | 12 | |||||
| NC | 0 | 0 | |||||
| . | . | . | Diagnosis . | Diagnostic performances . | |||
|---|---|---|---|---|---|---|---|
| . | . | . | TCL . | BTC . | Se (%) . | Sp (%) . | Accuracy (%) . |
| (95% CI) . | (95% CI) . | (95% CI) . | |||||
| Test cohort (N = 57) | PCR | + | 39 | 7 | 95.1 (83.5-99.4) | 41.7 (15.2-72.3) | 83.0 (70.2-91.9) |
| − | 2 | 5 | |||||
| NC | 3 | 1 | |||||
| t-NGS | + | 42 | 0 | 95.5 (84.5-99.4) | 100.0 (75.3-100.0)* | 96.5 (87.9-99.6) | |
| − | 2 | 13 | |||||
| NC | 0 | 0 | |||||
| Validation cohort (N = 50) | PCR | + | 35 | 6 | 94.6 (81.8-99.3) | 45.5 (16.7-76.6) | 83.3 (69.8-92.5) |
| − | 2 | 5 | |||||
| NC | 1 | 1 | |||||
| t-NGS | + | 37 | 0 | 97.4 (86.2-99.9) | 100.0 (73.5-100.0)* | 98.0 (89.4-99.9) | |
| − | 1 | 12 | |||||
| NC | 0 | 0 | |||||
1-sided 97.5% CI.
BTC, benign T-cell infiltrate; NC, noncontributory; Se, sensitivity; Sp, specificity; TCL, T-cell lymphoma.